DT120 Lysergide ODT Receives FDA Breakthrough Therapy Designation for Major Depressive Disorder
Major depressive disorder (MDD) remains a major source of disability, and many patients do not achieve remission with first-line treatment. Available antidepressants generally require ongoing dosing, may take several weeks to produce their full effect, and can be limited by tolerability. Against this background, Definium Therapeutics announced on September 8, 2026, that the US Food and Drug Administration (FDA) granted Breakthrough Therapy designation to DT120 (lysergide) orally disintegrating tablet (ODT) for MDD. This is the second such designation for the DT120 program, following an earlier designation in generalized anxiety disorder (GAD).
DT120 is a proprietary ODT formulation of lysergide, also known as lysergic acid diethylamide (LSD). It is an ergoline-derived classic serotonergic psychedelic and acts as a partial agonist at the serotonin 2A receptor. A 100-microgram dose produces transient changes in perception, cognition, and affect, so dosing in the clinical program occurs during a monitored session. Breakthrough Therapy designation is intended to expedite development and review when preliminary clinical evidence suggests that a drug for a serious condition may substantially improve a clinically meaningful outcome over available therapy. The designation provides more intensive FDA guidance and access to expedited development features; it is not marketing approval and does not establish that DT120 is safe or effective.
The designation was supported by sponsor-reported topline results from Emerge, a phase 3, multicenter, randomized, double-blind, placebo-controlled trial. Emerge enrolled 149 adults aged 18 to 74 years at 20 sites. Eligible participants had DSM-5-confirmed MDD, a Montgomery-Asberg Depression Rating Scale (MADRS) score of at least 26, and a Clinical Global Impression-Severity (CGI-S) score of at least 4 at screening and baseline. Participants received a single dose of DT120 ODT 100 micrograms (n=75) or placebo ODT (n=74) and entered a 12-week double-blind period, followed by a 40-week open-label extension in which additional dosing could be offered according to symptom severity. Mean baseline MADRS scores were 35.0 with DT120 and 34.0 with placebo.
Emerge MADRS outcomes after one supervised dose
| Time point |
DT120 100 micrograms |
Placebo |
Placebo-adjusted difference |
| Week 1 |
-17.6 |
-3.4 |
-14.2, P<.0001 |
| Week 6 (primary endpoint) |
-13.3 |
-5.2 |
-8.1, P<.0001 |
| Week 12 |
-11.0 |
-3.6 |
-7.3, P<.0001 |
Values are least-squares mean changes from baseline. Negative values indicate improvement. Results are company-reported topline data and have not yet undergone peer review.
Emerge met its primary endpoint. At week 6, the least-squares mean reduction in MADRS score was 13.3 points with DT120 and 5.2 points with placebo, a placebo-adjusted difference of 8.1 points (P<.0001). The separation was evident at week 1 and remained statistically significant at week 12. CGI-S results followed a similar pattern, with placebo-adjusted differences of 0.9 point at day 2, 0.9 point at week 6, and 0.7 point at week 12 (all P<.0001). At week 6, response, defined as at least a 50% reduction in MADRS score, occurred in 35% of the DT120 group and 7% of the placebo group (P<.001). Sponsor-defined remission occurred in 24% and 3%, respectively (P<.01).
Acute treatment effects were common. Sponsor materials reported at least one treatment-emergent adverse event in 99% of DT120 recipients and 57% of placebo recipients. Most events were mild or moderate and occurred on the dosing day. Frequently reported effects included illusion, euphoric mood, nausea, headache, anxiety, dizziness, disorientation, abnormal thinking, and increased blood pressure. One severe event, a recurrence of chronic back pain approximately six weeks after dosing, was reported in the DT120 group. No serious adverse events, deaths, treatment-emergent discontinuations, suicidal behavior, or signal for increased suicidal ideation were reported during the 12-week controlled phase. The sample size and duration, however, were insufficient to characterize uncommon or longer-term risks. Participants receiving DT120 met end-of-session discharge criteria after a mean of 5.8 hours, and all met the criteria by hour 8.
The GAD program provides supportive context but does not add direct evidence for MDD. In the phase 3 Voyage study, 214 adults with GAD received a single DT120 ODT 100-microgram dose or placebo. At week 12, the least-squares mean reduction in Hamilton Anxiety Rating Scale score was 11.6 points with DT120 and 6.2 points with placebo, a 5.4-point difference (P<.0001; Cohen d=0.81). Response rates were 43% and 16%, and remission rates were 14% and 4%, respectively. As in Emerge, monitoring occupied much of the dosing day: the mean time to discharge criteria was 6.4 hours, and 92% of treated participants were cleared by hour 8.
The magnitude and persistence of the Emerge results are encouraging, but several issues limit clinical interpretation. The findings have been released by the sponsor rather than published as a complete peer-reviewed report, so details needed to evaluate the analyses and generalizability remain limited. The distinctive acute effects of a 100-microgram lysergide dose also make functional unblinding and expectancy effects important concerns in a placebo-controlled psychedelic trial, even when outcome ratings use blinded central raters. Definium's second phase 3 MDD study, Ascend, includes a 50-microgram arm specifically intended to make dose assignment harder to identify. Emerge did not compare DT120 with an established antidepressant, and the controlled data extend only through 12 weeks after a single dose. Longer-term safety, the need and timing for repeat dosing, patient selection, and the practical requirements for treatment delivery remain unresolved.
Clinical takeaway: DT120 is a promising investigational treatment, but Breakthrough Therapy designation does not change current prescribing practice. A single supervised dose produced a large, rapid, and statistically significant antidepressant effect that persisted for 12 weeks in Emerge, alongside predictable acute psychedelic effects and a six-to-eight-hour monitoring requirement. Clinicians should await the second pivotal MDD trial, full peer-reviewed efficacy and safety data, and FDA review before drawing conclusions about the treatment's role. DT120 should not be used for MDD outside an authorized clinical trial.